Understanding how chromosomal instability affects radiation sensitivity in meningioma tumors
Official title: Chromosomal instability and radiation sensitivity in meningioma
Funded at University of California, San Francisco · NIH-11036124 · Data updated 2026-11-12
This study is looking at how a new test can help doctors figure out which patients with meningiomas, a common type of brain tumor, might do better with radiation therapy after surgery, so they can improve treatment options for those who need it.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $162,756 |
| NIH project number | 1K99CA296996-01 |
| Project ID | NIH-11036124 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with meningiomas, especially those with high-grade tumors or those who have undergone surgery.
✕Less likely to help
Patients with low-grade meningiomas or those who are not candidates for surgery or radiation therapy may not benefit from this research.
What this research studies
This research investigates meningiomas, the most common primary brain tumors, focusing on the challenges of predicting patient outcomes after surgery and the effectiveness of radiation therapy. The study aims to validate a new biomarker related to chromosomal instability that could better identify patients who would benefit from radiation treatment. By using advanced mouse models and human cell lines, the research will explore how chromosomal instability contributes to tumor growth and resistance to therapy. Ultimately, the goal is to improve treatment strategies for patients with high-grade meningiomas.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for meningioma patients, particularly those with high-grade tumors resistant to radiation therapy.
How similar studies have gone: Previous research has shown promising results in using biomarkers for risk stratification in other tumor types, suggesting potential success for this novel approach in meningiomas.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Chen, William C — University of California, San Francisco
- Study coordinator: Chen, William C
Related research
Other NIH-funded projects on the same topics.
-
Meningioma biology and new therapies guided by molecular profiling
A large, multi-institution study is exploring how meningiomas grow and respond to treatment, using advanced molecular profiling to find safer, more effective ways to manage them.
-
Biomarker-based guidance to predict meningioma outcomes and radiotherapy response
A gene-based test is being developed to help predict how meningioma tumors will behave and how patients may respond to radiotherapy.
-
Meningioma radiotherapy response: understanding gene clues and how to tailor treatment
A short research project will study why some meningioma tumors respond differently to radiotherapy by looking at gene activity and how it affects treatment outcomes.
-
Genomic and biochemical clues behind meningioma race differences and outcomes
This grant aims to uncover biological and environmental factors that cause differences in meningioma occurrence and treatment results across racial groups, with the goal of improving care for patients affected by this brain tumor.
-
How the MN1 protein drives aggressive acute myeloid leukemia
This project looks at how the MN1 protein and its partner BAF complex keep leukemia genes active in people with acute myeloid leukemia to reveal new treatment targets.
-
How meningiomas change over time and new treatment targets
This project looks for molecular signs that predict which meningiomas will come back and finds drug targets to help people with aggressive or recurrent tumors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.